If there were a “drug of the summer” award, Ozempic would win hands down. This Glucagon-Like Peptide 1 (GLP-1) receptor agonist, scientifically known as Semaglutide, was originally developed to treat type 2 diabetes. Today, it’s better known for delivering rapid, dramatic weight loss.
But Ozempic’s meteoric rise has brought increased scrutiny. Its manufacturer, Novo Nordisk, now faces a flood of lawsuits. Patients are alleging a wide range of side effects, from digestive issues to the more alarming claim of irreversible vision loss.
As Ozempic remains a focal point of ongoing medical research and cultural conversation, these lawsuits have placed the drug at the heart of a high-stakes legal battle. Here’s what you need to know about the controversy that’s reshaping public perception and corporate accountability.
